October 14, 2019
Mogrify raises additional $16M, (total $20M) in series A funding
Mogrify has raised additional $16 million to advance its mission to transform the development of life-saving cell therapies, with initial…
Pharmaceuticals, Biotechnology and Life Sciences
Category: Europe
October 14, 2019
Novigenix and RadioMedix set to work on neuroendocrine cancer precision diagnostic test
Novigenix and RadioMEdix have announced collaboration on developing a test to measure response to radiopharmaceutical therapy, based on Novigenix’s technology.
October 10, 2019
MGB Biopharma sees promising results from phase IIa clinical trial for potent oral bactericidal antibiotic targeting CDAD
MGB Biopharma has announced promising phase IIa clinical trial update for oral formulation MGB-BP-3, a potent oral bactericidal antibiotic targeting Clostridium Difficile-Associated Diarrhoea (CDAD), with – as it said in a press release – a completely novel mode of action.
October 10, 2019
Heidelberg Pharma doubles revenue, net loss falls to €5.6, in first nine months
Heidelberg Pharma reported that its net loss for the first nine months of the fiscal year fell to €5.6 million from previous year’s €7.4 million, referring the result to the sales revenue and income totaling €6.7 million, from €3.5 million in the same period last year.
October 9, 2019
Shionogi: cefiderocol met primary endpoint in phase III study in adults with nosocomial pneumonia
Shionogi has reported positive Results from Cefiderocol Phase III study in adults with nosocomial pneumonia caused by gram-negative pathogens, as cefiderocol met primary endpoint of non-inferiority in 14-day all-cause mortality compared to high-dose meropenem.
October 8, 2019
Novartis gets FDA’s approval for Beovu for AMD patients
Novartis has received FDA approval for Beovu, the only anti-VEGF in wet AMD recommended to maintain eligible patients on up to three-month dosing intervals immediately after the loading phase with no compromise in efficacy, for AMD patients, which are in risk from causes blindness and loss of independence.
October 7, 2019
Biom’up’s Hemoblasttem Bellows approved in Australia
Biom’up SA, a specialist in surgical hemostasis, announces its flagship product, HEMOBLAST Bellows, has been approved for open as well as laparoscopic surgery by the Australian TGA regulatory authority for commercialization in the sizeable and growing Australian market.
October 7, 2019
AveXis has early encouraging results for spinal muscular atrophy patients treatment
Novartis’ company Avexis said that it’s Phase 1/2 Srong study for intrathecal (IT) administration of AVXS-101, showed that patients aged 2 to 5, with spinal muscular atrophy (SMA) Type 2 achieved a mean increase of 5.9 points from baseline in HFMSE scores, nearly double the clinically meaningful threshold, at a mean duration of follow-up time of 9.3 months.
October 1, 2019
Debiopharm’s novel IAP antagonist Debio 1143 met trial goals
Swiss-based biopharmaceutical drugmaker Debiopharm presented results for its novel IAP antagonist Debio 1143 from phase two trial, for high-risk Head and Neck cancer patients, which met its primary goal of increasing treatment efficacy compared to CRT and placebo.
October 1, 2019
Sobi buys Dova Pharmaceuticals for $915 million
Swedish Orphan Biovitrum (Sobi) said Monday it will Dova Pharmaceuticals for an upfront payment of $27.50 per share in cash and, one non-tradeable Contingent Value Right (CVR), with an additional $1.50 for shareholders upon approval of Doptelet for use in Chemotherapy-Induced Thrombocytopenia (CIT) by the US Food and Drug Administration (FDA).